Sponsored Links
Lymphoma Information Network » Lymphoma Info » Mantle Cell Lymphoma

Mantle Cell Lymphoma

lymph node diagram
Lymph node diagram

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes, which is the outer ring of lymphocytes in a node. The cancer begins in the mantle zone but may spread to the spleen, liver, bone marrow, and GI tract. It is generally a low-grade, indolent cancer but it can be more aggressive than other slow-growing tumors.

Mantle cell lymphoma accounts for about 1 in 20 Non-Hodgkin’s Lymphoma diagnoses in the United States; it has a higher occurrence in Europe. It typically occurs in patients over 30 years old, and is more frequent in patients over 50. Males are three times more likely to be diagnosed than females. Research is still being conducted to find affective treatments, as it has one of the poorer prognoses of the lymphomas.

Diagnosis and Staging

Patients usually present with symptoms common to all lymphomas: swollen glands, night sweats, weight loss, and fevers. Patients with mantle cell lymphoma may present with appetite loss as well because of the common involvement of the GI tract.

A doctor will take a biopsy to diagnose the disease. The biopsy will remove a portion of an affect lymph node or the whole lymph node for examination under a microscope.

Once a diagnosis of MCL is confirmed, the doctor may use other tests, such as blood tests, CT scans, PET scans, and/or bone marrow biopsies to determine the extent of the cancer in order to stage it.

Like most other lymphomas, staging depends on the spread of the lymphoma. If only one group of nodules in the lymph system is involved, then the disease is Stage I. Stage II disease includes the involvement of two lymph groups on the same side of the diaphragm, which divides the body into upper and lower sections. Or, one lymph group and the spleen may be involved in Stage II. Stage III disease is indicated by tumors in lymph groups on both sides of the diaphragm. Stage IV involves spread to other organs, such as the liver or bone marrow.

The disease is grade “A” if there are no common symptoms, such as night sweats. It is grade “B” if those symptoms are present. There is a third grade – grade “E”, which stands for extranodal – that indicates the cancer began in organs other than the lymph nodes; that is possible in MCL.

Treatments

The treatment method depends on the stage of the disease. There are many clinical trials, as affective treatments for this disease are still being researched.

Pharmatech assists lymphoma patients in identifying clinical studies. Follow this link to identify a conveniently located cancer treatment center and begin the process of enrollment.

The radioimmunotherapy regimen Zevalin® is currently being researched as a treatment for mantle-cell lymphoma.

Common treatment approaches include:

  • Monoclonal antibody treatment using drugs such as Rituximab, which trains the body’s immune system to target and destroy cancer cells.
  • Interferon, which is an immune system booster, is sometimes injected into patients to help them fight the disease.
  • Chemotherapy agents, such as the R-CHOP, or FCR regiments. R-CHOP combines Rituximab with a steroid, Prednisone, and three chemotherapy agents: cyclophosphamide, vincritine, and doxorubicin. FCR uses cyclophosphamide, Rituximab, and a newer chemotherapy drug called Fludarabine.
  • Radiation treatment is typically used in Stage I or II patients as a stand alone treatment, or in combination with chemotherapy in the later stages of the disease.
  • Stem Cell Therapy is an aggressive therapy used for late stages of the disease.

Sponsored Links

Cancer Support Groups

SupportGroups.com aims to build awareness and provide support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. If you are a friend or parent of a person that has been diagnosed with Lymphoma, or you have been diagnosed with Lymphoma, you are not alone. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Dive Deeper

Non-Hodgkin's Lymphoma Information

disclaimer

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.

Featured Treatment
searching for treatment

Featured Treatment: Zevalin®

Zevalin® (Ibritumomab tiuxetan) is a form of radioimmunotherapy (a radiolabeled monoclonal antibody) for treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL). "Refractory" refers to a disease that does not respond to treatment.

Zevalin is the first radioummunotherapy treatment to be FDA-approved as a first-line therapy for lymphoma. Read more...

Sponsored Links
User login
Cancer Support Groups

Cancer Support Groups

support groups

SupportGroups.com aims to build awareness and provide support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. If you are a friend or parent of a person that has been diagnosed with Lymphoma, or you have been diagnosed with Lymphoma, you are not alone. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Poll
What is most important to you in an Online Support Group?:
Latest Blog Entries
Did You Know?
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Incidence rates for Hodgkin’s disease have declined about 60%. Better means of diagnosis has also increased the number as doctors better understand cancer of lymphocytes verses other diseases.